Lisata Therapeutics (LSTA) Competitors $2.26 +0.18 (+8.65%) Closing price 04/17/2025 03:56 PM EasternExtended Trading$2.12 -0.14 (-5.97%) As of 04/17/2025 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LSTA vs. ABOS, IFRX, BMEA, SAVA, VTGN, JSPR, IVVD, VHAQ, INZY, and ALTSShould you be buying Lisata Therapeutics stock or one of its competitors? The main competitors of Lisata Therapeutics include Acumen Pharmaceuticals (ABOS), InflaRx (IFRX), Biomea Fusion (BMEA), Cassava Sciences (SAVA), Vistagen Therapeutics (VTGN), Jasper Therapeutics (JSPR), Invivyd (IVVD), Viveon Health Acquisition (VHAQ), Inozyme Pharma (INZY), and Janone (ALTS). These companies are all part of the "pharmaceutical products" industry. Lisata Therapeutics vs. Acumen Pharmaceuticals InflaRx Biomea Fusion Cassava Sciences Vistagen Therapeutics Jasper Therapeutics Invivyd Viveon Health Acquisition Inozyme Pharma Janone Acumen Pharmaceuticals (NASDAQ:ABOS) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, community ranking, dividends and institutional ownership. Do institutionals and insiders believe in ABOS or LSTA? 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are owned by institutional investors. 7.1% of Acumen Pharmaceuticals shares are owned by insiders. Comparatively, 9.1% of Lisata Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is ABOS or LSTA more profitable? Acumen Pharmaceuticals' return on equity of -32.99% beat Lisata Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Acumen PharmaceuticalsN/A -32.99% -27.99% Lisata Therapeutics N/A -51.19%-45.16% Does the MarketBeat Community believe in ABOS or LSTA? Acumen Pharmaceuticals received 13 more outperform votes than Lisata Therapeutics when rated by MarketBeat users. However, 93.33% of users gave Lisata Therapeutics an outperform vote while only 72.97% of users gave Acumen Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAcumen PharmaceuticalsOutperform Votes2772.97% Underperform Votes1027.03% Lisata TherapeuticsOutperform Votes1493.33% Underperform Votes16.67% Do analysts recommend ABOS or LSTA? Acumen Pharmaceuticals presently has a consensus target price of $7.33, indicating a potential upside of 714.09%. Lisata Therapeutics has a consensus target price of $15.00, indicating a potential upside of 563.72%. Given Acumen Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Acumen Pharmaceuticals is more favorable than Lisata Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acumen Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Lisata Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation & earnings, ABOS or LSTA? Lisata Therapeutics has higher revenue and earnings than Acumen Pharmaceuticals. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcumen PharmaceuticalsN/AN/A-$52.37M-$1.71-0.53Lisata Therapeutics$1M19.48-$20.84M-$2.40-0.94 Which has more risk & volatility, ABOS or LSTA? Acumen Pharmaceuticals has a beta of 0.1, suggesting that its stock price is 90% less volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500. Does the media prefer ABOS or LSTA? In the previous week, Lisata Therapeutics had 4 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 4 mentions for Lisata Therapeutics and 0 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 1.47 beat Lisata Therapeutics' score of 0.17 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Acumen Pharmaceuticals Positive Lisata Therapeutics Neutral SummaryAcumen Pharmaceuticals beats Lisata Therapeutics on 11 of the 17 factors compared between the two stocks. Get Lisata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LSTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LSTA vs. The Competition Export to ExcelMetricLisata TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.48M$6.46B$5.31B$7.35BDividend YieldN/A3.22%5.47%4.31%P/E Ratio-0.906.9521.9417.82Price / Sales19.48231.01380.9497.71Price / CashN/A65.6738.3134.64Price / Book0.385.936.453.98Net Income-$20.84M$143.22M$3.22B$247.81M7 Day Performance15.90%4.28%5.85%3.19%1 Month Performance-0.88%-13.11%-9.58%-7.70%1 Year Performance-16.30%-8.51%11.85%1.49% Lisata Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LSTALisata Therapeutics2.1832 of 5 stars$2.26+8.7%$15.00+563.7%-16.3%$19.48M$1M-0.9030News CoveragePositive NewsABOSAcumen Pharmaceuticals3.1991 of 5 stars$1.10-0.9%$7.33+566.7%-71.4%$67.24MN/A-0.8020Positive NewsIFRXInflaRx2.1904 of 5 stars$0.98+6.0%$9.00+818.5%-21.5%$65.78M$165,789.00-0.9160Short Interest ↑BMEABiomea Fusion1.959 of 5 stars$1.62-7.4%$23.91+1,375.9%-84.5%$65.75MN/A-0.4050SAVACassava Sciences3.503 of 5 stars$1.34+5.5%$54.50+3,967.2%-92.7%$64.73MN/A-0.9730VTGNVistagen Therapeutics1.0885 of 5 stars$2.23+5.2%N/A-55.7%$64.36M$698,000.00-1.5140News CoverageJSPRJasper Therapeutics1.9616 of 5 stars$4.20+1.0%$62.50+1,388.1%-81.6%$63.09MN/A-0.8920IVVDInvivyd2.3773 of 5 stars$0.53-4.4%$7.52+1,331.5%-77.8%$62.99M$25.38M-0.27100Short Interest ↑Negative NewsGap UpVHAQViveon Health AcquisitionN/A$11.00flatN/A+22.2%$62.26MN/A0.002High Trading VolumeINZYInozyme Pharma3.0232 of 5 stars$0.97+9.4%$14.63+1,409.1%-79.6%$62.26MN/A-0.6250News CoverageALTSJanoneN/A$3.85flatN/AN/A$61.90M$12.53M0.00170Short Interest ↑News Coverage Related Companies and Tools Related Companies Acumen Pharmaceuticals Competitors InflaRx Competitors Biomea Fusion Competitors Cassava Sciences Competitors Vistagen Therapeutics Competitors Jasper Therapeutics Competitors Invivyd Competitors Viveon Health Acquisition Competitors Inozyme Pharma Competitors Janone Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LSTA) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lisata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lisata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
